Table 1 Demographic and clinicopathological features of 403 patients who underwent PDAC resection categorized according to recurrence-free time
| Â | Recurrence-free duration | ||||
|---|---|---|---|---|---|
<6 months (n=59) | 6 to 12 months (n=94) | no rec or later (n=250) | p-value | ||
Age in years, median(IQR) | 71 (64-75) | 70 (62.25-75.75) | 71 (66-76.75) | 0.435 | |
Gender, n(%) | Male | 34 (57.6%) | 60 (63.8%) | 116 (46.4%) | 0.01 |
Female | 25 (42.4%) | 34 (36.2%) | 134 (53.6%) | ||
BMI | 21.73 | 21.64 | 21.50 | 0.844 | |
Neoadjuvant therapy, n(%) | Yes | 22 (37.3%) | 37 (39.4%) | 84 (33.6%) | 0.58 |
No | 37 (62.7%)) | 57 (60.6%) | 166 (66.4%) | ||
NAC regimen, n(%) | GS | 13 (56.5%) | 26 (70.2%) | 58 (68.2%) | 0.322 |
GnP | 7 (30.4%) | 8 (21.6%) | 13 (15.3%) | ||
GEM | 0 (0%) | 1 (2.7%) | 2 (2.4%) | ||
S-1+Radiation | 2 (8.7%) | 2 (5.4%) | 11 (12.9%) | ||
preoperative CA19-9(U/l), median(IQR) | 331.5 (84.75 – 1354.25) | 165.6 (51.25 – 877.65) | 70.9 (16.2 – 389.85) | <0.001 | |
mGPS, n(%) | 0 | 38 (64.4%) | 67 (71.3%) | 204 (81.6%) | 0.001 |
1 | 10 (16.9%) | 21 (22.3%) | 33 (13.2%) | ||
2 | 11 (18.6%) | 6 (6.4%) | 13 (5.2%) | Â | |
Resectability, n(%) | R | 44 (74.6%) | 66 (70.2%) | 208 (83.2%) | 0.021 |
BR | 15 (25.4%) | 28 (29.8%) | 42 (16.8%) | ||
Surgical procedure, n(%) | SSPPD | 34 (57.6%) | 64 (68.1%) | 169 (67.6%) | 0.643 |
DP | 21 (35.6%) | 25 (26.6%) | 73 (29.2%) | ||
TP | 4 (6.8%) | 5 (5.3%) | 8 (3.2%) | ||
Vascular resection, n(%) | No | 43 (72.9%) | 58 (61.7%) | 196 (78.4%) | 0.004 |
Venous | 14 (23.7%) | 36 (38.3%) | 52 (20.8%) | ||
Arterial | 2 (3.4%) | 0 (0%) | 2 (0.8%) | ||
Major complication (Clavien-Dindo>IIIa), n(%) | Yes | 21 (35.6%) | 22 (23.4%) | 53 (21.2%) | 0.065 |
No | 38 (64.4%) | 72 (76.6%) | 197 (78.8%) | ||
POPF, n(%) | 0 | 41 (69.5%) | 58 (61.7%) | 154 (61.6%) | 0.106 |
BL | 2 (3.4%) | 15 (16%) | 31 (12.4%) | ||
B | 14 (23.7%) | 19 (20.2%) | 64 (25.6%) | ||
C | 2 (3.4%) | 2 (2.1%) | 1 (0.4%) | ||
Size of tumor (mm), median(IQR) | 38 (31.5 – 51) | 32 (28 – 45) | 30 (23 – 38) | <0.001 | |
Histological type, n(%) | tub | 34 (57.6%) | 76 (80.8%) | 205 (82.0%) | <0.001 |
por | 17 (28.8%) | 15 (16.0%) | 28 (11.2%) | ||
others | 8 (13.6%) | 3 (3.2%) | 17 (6.8%) | ||
T factor TNM 8th edition, n(%) | 1 | 3 (5.1%) | 9 (9.6%) | 47 (18.8%) | <0.001 |
2 | 29 (49.2%) | 60 (63.8%) | 154 (61.6%) | ||
3 | 27 (45.8%) | 25 (26.6%) | 49 (19.6%) | ||
N factor TNM 8th edition, n(%) | 0 | 12 (20.3%) | 19 (20.2%) | 101 (40.4%) | <0.001 |
1 | 24 (40.7%) | 43 (45.7%) | 108 (43.2%) | ||
2 | 23 (39.0%) | 32 (34.0%) | 41 (16.4%) | ||
Peritoneal cytology, n(%) | positive | 13 (22.4%) | 10 (10.8%) | 10 (4.0%) | <0.001 |
negative | 45 (77.6%) | 83 (89.2%) | 238 (96.0%) | ||
Resection margin, n(%) | positive | 17 (28.8%) | 25 (26.6%) | 48 (19.2%) | 0.147 |
negative | 42 (71.2%) | 69 (73.4%) | 202 (80.8%) | ||
Duration of hospital stay, median(IQR) | 16 (13 – 23) | 17 (13.25 – 23) | 17 (13.5 – 28.5) | 0.487 | |
Adjuvant chemotherapy, n(%) | Yes | 37 (62.7%) | 88 (93.6%) | 240 (96.0%) | 0.001 |
No | 22 (37.3%) | 6 (6.4%) | 10 (4.0%) | ||
Recurrence cite, n(%) | Liver | 27 (45.8%) | 26 (27.7%) | 18 (14.2%) | <0.001 |
Multiple | 14 (23.7%) | 26 (27.7%) | 24 (18.9%) | ||
Local | 5 (8.5%) | 17 (18.1%) | 27 (21.3%) | ||
Lung | 3 (5.1%) | 5 (5.3%) | 25 (19.7%) | ||
Peritoneum | 7 (11.9%) | 6 (6.4%) | 11 (8.7%) | ||
Lymph node | 3 (5.1%) | 13 (13.8%) | 21 (16.5%) | ||
Others | 0 (0%) | 1 (1.1%) | 1 (0.8%) | ||
Treatment after recurrence, n(%) | Yes | 47 (79.7%) | 82 (87.2%) | 114 (90.5%) | 0.123 |
No | 12 (20.3%) | 12 (12.8%) | 12 (9.5%) | ||